Company intelligence / Profile preview
Aurion Biotech
Seattle, Washington, United Statesaurionbiotech.com ↗
- Ownership
- Private
- Employees
- ~67
- Development stage
- Other
01
Overview
Aurion has developed AURN001, an investigational single administration allogeneic combination cell therapy product comprising human corneal endothelial cells and a ROCK inhibitor. Their first-generation product HCEC‑1 was approved and launched commercially in Japan as Vyznova in September 2024. The next-generation candidate AURN001 has completed Phase I/II CLARA trial enrollment with positive safety/tolerability results supporting advancement into Phase III. The company received FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation for AURN001[2][3][4][6][9].
- Therapeutic areas
- Ophthalmology
- Modalities
- Allogeneic cell therapyCombination cell therapy with ROCK inhibitor
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Alcon partnership providing R&D, regulatory, medical ophthalmology expertise and commercial capabilities[4]
Beyond the preview
Go deeper on Aurion Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurion Biotech.